EP3509594C0 - LYSYL OXIDASE HOMOLOGUE 2 INHIBITOR FOR USE IN THE TREATMENT OF MYELOFIBROSIS - Google Patents

LYSYL OXIDASE HOMOLOGUE 2 INHIBITOR FOR USE IN THE TREATMENT OF MYELOFIBROSIS

Info

Publication number: EP3509594C0
Authority: EP; European Patent Office
Prior art keywords: myelofibrosis; inhibitor; treatment; lysyl oxidase; oxidase homologue
Prior art date: 2016-09-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

EP17849478.7A

Other languages

German (de)

French (fr)

Other versions

EP3509594A4 (en

EP3509594A1 (en

EP3509594B1 (en

Inventor

Gretchen Bain

Jillian Frances Evans

Deidre A Mackenna

John Howard Hutchinson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmakea Inc

Original Assignee

Pharmakea Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-09-07

Filing date

2017-09-06

Publication date

2025-02-26

2017-09-06 Application filed by Pharmakea Inc filed Critical Pharmakea Inc

2017-09-06 Priority to EP24171603.4A priority Critical patent/EP4385571A3/en

2017-09-06 Priority to EP22168167.9A priority patent/EP4052707A1/en

2019-07-17 Publication of EP3509594A1 publication Critical patent/EP3509594A1/en

2020-05-06 Publication of EP3509594A4 publication Critical patent/EP3509594A4/en

2025-02-26 Application granted granted Critical

2025-02-26 Publication of EP3509594B1 publication Critical patent/EP3509594B1/en

2025-02-26 Publication of EP3509594C0 publication Critical patent/EP3509594C0/en

Status Active legal-status Critical Current

2037-09-06 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)

EP17849478.7A 2016-09-07 2017-09-06 A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis Active EP3509594B1 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
EP24171603.4A EP4385571A3 (en)	2016-09-07	2017-09-06	Uses of a lysyl oxidase-like 2 inhibitor related applications
EP22168167.9A EP4052707A1 (en)	2016-09-07	2017-09-06	Uses of a lysyl oxidase-like 2 inhibitor

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662384542P	2016-09-07	2016-09-07
US201762509460P	2017-05-22	2017-05-22
PCT/US2017/050331 WO2018048942A1 (en)	2016-09-07	2017-09-06	Uses of a lysyl oxidase-like 2 inhibitor

Related Child Applications (4)

Application Number	Title	Priority Date	Filing Date
EP24171603.4A Division EP4385571A3 (en)	2016-09-07	2017-09-06	Uses of a lysyl oxidase-like 2 inhibitor related applications
EP24171603.4A Division-Into EP4385571A3 (en)	2016-09-07	2017-09-06	Uses of a lysyl oxidase-like 2 inhibitor related applications
EP22168167.9A Division EP4052707A1 (en)	2016-09-07	2017-09-06	Uses of a lysyl oxidase-like 2 inhibitor
EP22168167.9A Division-Into EP4052707A1 (en)	2016-09-07	2017-09-06	Uses of a lysyl oxidase-like 2 inhibitor

Publications (4)

Publication Number	Publication Date
EP3509594A1 EP3509594A1 (en)	2019-07-17
EP3509594A4 EP3509594A4 (en)	2020-05-06
EP3509594B1 EP3509594B1 (en)	2025-02-26
EP3509594C0 true EP3509594C0 (en)	2025-02-26

Family

ID=61561650

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP22168167.9A Pending EP4052707A1 (en)	2016-09-07	2017-09-06	Uses of a lysyl oxidase-like 2 inhibitor
EP24171603.4A Pending EP4385571A3 (en)	2016-09-07	2017-09-06	Uses of a lysyl oxidase-like 2 inhibitor related applications
EP17849478.7A Active EP3509594B1 (en)	2016-09-07	2017-09-06	A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
EP22168167.9A Pending EP4052707A1 (en)	2016-09-07	2017-09-06	Uses of a lysyl oxidase-like 2 inhibitor
EP24171603.4A Pending EP4385571A3 (en)	2016-09-07	2017-09-06	Uses of a lysyl oxidase-like 2 inhibitor related applications

Country Status (13)

Country	Link
US (3)	US11793797B2 (en)
EP (3)	EP4052707A1 (en)
JP (1)	JP7097874B2 (en)
KR (2)	KR20230162996A (en)
CN (2)	CN117180280A (en)
AU (1)	AU2017324444A1 (en)
BR (1)	BR112019004513A2 (en)
CA (1)	CA3036062A1 (en)
ES (1)	ES3015717T3 (en)
IL (1)	IL265232A (en)
MA (1)	MA46203A (en)
MX (1)	MX2019002612A (en)
WO (1)	WO2018048942A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3795568A1 (en)	2015-03-06	2021-03-24	Pharmakea, Inc.	Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
JP6800872B2 (en) *	2015-03-06	2020-12-16	ファーマケア，インク．	Lysyl oxidase-like 2 inhibitor and its use
CA3013917A1 (en)	2016-02-09	2017-08-17	Pharmakea, Inc.	Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
AU2017324445A1 (en)	2016-09-07	2019-04-11	Pharmakea, Inc.	Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
JP7097874B2 (en)	2016-09-07	2022-07-08	ファーマケア，インク．	Use of lysyl oxidase-like 2 inhibitor
US20210002641A1 (en) *	2018-03-16	2021-01-07	The Regents Of The University Of Michigan	Compositions and methods for treating graves disease
CN112441916A (en) *	2019-08-29	2021-03-05	广东药科大学	Novel phenylacetic acid derivatives, method for the production thereof and use thereof as medicaments
EP4031124A4 (en) *	2019-09-20	2024-01-24	Reneo Pharmaceuticals, Inc.	USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF KIDNEY DISEASE
WO2021086973A2 (en) *	2019-10-28	2021-05-06	University Of Iowa Research Foundation	Formulation for delivery of lubricin gene
CN110714016B (en) *	2019-11-29	2021-08-20	长沙学院	JNK gene and its application as a diagnostic molecular marker and therapeutic target for bacterial enteritis in fish
CN112662763A (en) *	2020-03-10	2021-04-16	博尔诚（北京）科技有限公司	Probe composition for detecting common amphoteric cancers
WO2022117865A1 (en) *	2020-12-03	2022-06-09	Delta 4 Gmbh	Saroglitazar and myristic acid for use in the treatment of focal segmental glomerulosclerosis (fsgs)
WO2023196963A1 (en) *	2022-04-08	2023-10-12	The Regents Of The University Of California	Combination metabolic-epigenetic treatment for early lung cancer

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4229447A (en)	1979-06-04	1980-10-21	American Home Products Corporation	Intraoral methods of using benzodiazepines
IE56702B1 (en)	1982-12-01	1991-11-06	Usv Pharma Corp	Antiinflammatory antiallergic compounds
US4596795A (en)	1984-04-25	1986-06-24	The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services	Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en)	1986-01-22	1988-07-05	Schering Corporation	Buccal formulation
US5021456A (en)	1988-02-25	1991-06-04	Merrell Dow Pharmaceuticals Inc.	Inhibitors of lysyl oxidase
US5739136A (en)	1989-10-17	1998-04-14	Ellinwood, Jr.; Everett H.	Intraoral dosing method of administering medicaments
US5250532A (en)	1991-04-11	1993-10-05	Dowelanco	3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
US5563143A (en)	1994-09-21	1996-10-08	Pfizer Inc.	Catechol diether compounds as inhibitors of TNF release
US5691364A (en)	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
US7067664B1 (en)	1995-06-06	2006-06-27	Pfizer Inc.	Corticotropin releasing factor antagonists
US6956047B1 (en)	1995-06-06	2005-10-18	Pfizer Inc.	Corticotropin releasing factor antagonists
US6632823B1 (en)	1997-12-22	2003-10-14	Merck & Co., Inc.	Substituted pyridine compounds useful as modulators of acetylcholine receptors
HRP20020599A2 (en)	2000-01-18	2004-08-31	Pfizer Prod Inc	Corticotropin releasing factor antagonists
US6878714B2 (en)	2001-01-12	2005-04-12	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US6995162B2 (en)	2001-01-12	2006-02-07	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US20020147198A1 (en)	2001-01-12	2002-10-10	Guoqing Chen	Substituted arylamine derivatives and methods of use
US7102009B2 (en)	2001-01-12	2006-09-05	Amgen Inc.	Substituted amine derivatives and methods of use
US7105682B2 (en)	2001-01-12	2006-09-12	Amgen Inc.	Substituted amine derivatives and methods of use
US20030134836A1 (en)	2001-01-12	2003-07-17	Amgen Inc.	Substituted arylamine derivatives and methods of use
TWI319387B (en)	2002-04-05	2010-01-11	Astrazeneca Ab	Benzamide derivatives
US7307088B2 (en)	2002-07-09	2007-12-11	Amgen Inc.	Substituted anthranilic amide derivatives and methods of use
FI20030030A0 (en)	2003-01-09	2003-01-09	Orion Corp	New compounds
ATE537825T1 (en)	2003-05-19	2012-01-15	Irm Llc	IMMUNOSUPPRESSIVE COMPOUNDS AND COMPOSITIONS
BRPI0507250A (en)	2004-01-29	2007-06-26	Pfizer Prod Inc	combinations to treat snc disorders
US7381750B2 (en)	2004-03-12	2008-06-03	Eli Lilly And Company	Amino-phenoxymethyl-benzamide opioid receptor antagonists
ATE545413T1 (en)	2004-03-15	2012-03-15	Lilly Co Eli	ANTAGONISTS OF THE OPIOID RECEPTOR
CA2564085C (en)	2004-04-30	2013-04-02	Takeda Pharmaceutical Company Limited	Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
US7507748B2 (en)	2004-07-22	2009-03-24	Amgen Inc.	Substituted aryl-amine derivatives and methods of use
MX2007002842A (en)	2004-09-10	2007-04-30	Pfizer Prod Inc	Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives.
WO2006027691A2 (en)	2004-09-10	2006-03-16	Pfizer Products Inc.	Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds
WO2006052546A2 (en)	2004-11-04	2006-05-18	Neurogen Corporation	Pyrazolylmethyl heteroaryl derivatives
DE102004056226A1 (en)	2004-11-22	2006-05-24	Burchardt, Elmar Reinhold, Dr.Dr.	Novel inhibitors of lysyl oxidase
AU2006210954A1 (en)	2005-01-31	2006-08-10	Merck & Co., Inc.	Antidiabetic bicyclic compounds
AR055041A1 (en)	2005-03-23	2007-08-01	Merck Frosst Canada Ltd	TIADIAZOLS AND OXADIAZOLS AS INHIBITORS OF THE SYNTHESIS OF LEUCOTRIENOS. PHARMACEUTICAL COMPOSITIONS.
AU2006279211A1 (en)	2005-08-11	2007-02-15	Merck Frosst Canada Ltd	Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors
US7405302B2 (en)	2005-10-11	2008-07-29	Amira Pharmaceuticals, Inc.	5-lipoxygenase-activating protein (FLAP) inhibitors
ITMI20051943A1 (en)	2005-10-14	2007-04-15	Procos Spa	ANANTIOMERIC RESOLUTION PROCESS OF 2-AMINOMETHYL-PYRROLIDINES 1-SUBSTITUTED FOR DAMAGE IN THE PRESENCE OF LIPASE
US20070219206A1 (en)	2005-11-04	2007-09-20	Amira Pharmaceuticals, Inc.	5-lipoxygenase-activating protein (flap) inhibitors
US20070225285A1 (en)	2005-11-04	2007-09-27	Amira Pharmaceuticals, Inc.	5-lipoxygenase-activating protein (flap) inhibitors
US7977359B2 (en)	2005-11-04	2011-07-12	Amira Pharmaceuticals, Inc.	5-lipdxygenase-activating protein (FLAP) inhibitors
CA2636043A1 (en)	2006-01-23	2007-08-02	Amira Pharmaceuticals, Inc.	Tricyclic inhibitors of 5-lipoxygenase
GB0614579D0 (en)	2006-07-21	2006-08-30	Black James Foundation	Pyrimidine derivatives
WO2008020799A1 (en)	2006-08-18	2008-02-21	Astrazeneca Ab	Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
IL184627A0 (en)	2007-07-15	2008-12-29	Technion Res & Dev Foundation	Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
CN110372795A (en)	2007-08-02	2019-10-25	吉利德生物制剂公司	LOX and LOXL2 inhibitor and its application
JP2013500974A (en)	2009-07-28	2013-01-10	アナコールファーマシューティカルズ，インコーポレイテッド	Trisubstituted boron-containing molecules
AU2010284001A1 (en) *	2009-08-21	2012-03-22	Gilead Biologics, Inc.	Therapeutic methods and compositions
RU2015108348A (en)	2010-02-04	2015-07-20	Джилид Байолоджикс, Инк.	ANTIBODIES BINDING WITH LYSYLOXIDASE-LIKE ENZYME-2 (LOXL2), AND WAYS OF THEIR APPLICATION
EP2534145A4 (en)	2010-02-08	2013-09-11	Kinagen Inc	Therapeutic methods and compositions involving allosteric kinase inhibition
CN103002742B (en)	2010-03-05	2016-07-13	卡尔约药物治疗公司	Nuclear translocation regulator and application thereof
WO2011150201A2 (en)	2010-05-27	2011-12-01	Ambit Biosciences Corporation	Azolyl amide compounds and methods of use thereof
EP2441755A1 (en)	2010-09-30	2012-04-18	Almirall, S.A.	Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
CN103415515B (en)	2010-11-19	2015-08-26	因塞特公司	Cyclobutyl-substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
TW201313721A (en)	2011-08-18	2013-04-01	Incyte Corp	Cyclohexyl azetidine derivatives as JAK inhibitors
WO2013059587A1 (en)	2011-10-20	2013-04-25	Sirtris Pharmaceuticals, Inc.	Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
US9701658B2 (en)	2012-04-25	2017-07-11	Raqualia Pharma Inc.	Amide derivatives as TTX-S blockers
SG11201503065PA (en)	2012-10-30	2015-05-28	Gilead Sciences Inc	Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
WO2014098098A1 (en)	2012-12-18	2014-06-26	味の素株式会社	Heterocyclic amide derivative, and medicine containing same
CA2939655A1 (en)	2014-02-14	2016-02-11	The University Of British Columbia	Modulators of caspase-6
US9051320B1 (en) *	2014-08-18	2015-06-09	Pharmakea, Inc.	Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
CN107922392B (en)	2015-02-15	2020-07-21	豪夫迈·罗氏有限公司	1-(Hetero)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and uses thereof
JP6800872B2 (en)	2015-03-06	2020-12-16	ファーマケア，インク．	Lysyl oxidase-like 2 inhibitor and its use
EP3795568A1 (en) *	2015-03-06	2021-03-24	Pharmakea, Inc.	Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
JP7097874B2 (en)	2016-09-07	2022-07-08	ファーマケア，インク．	Use of lysyl oxidase-like 2 inhibitor
AU2017324445A1 (en)	2016-09-07	2019-04-11	Pharmakea, Inc.	Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making

2017
- 2017-09-06 JP JP2019512639A patent/JP7097874B2/en active Active
- 2017-09-06 CA CA3036062A patent/CA3036062A1/en active Pending
- 2017-09-06 EP EP22168167.9A patent/EP4052707A1/en active Pending
- 2017-09-06 WO PCT/US2017/050331 patent/WO2018048942A1/en not_active Ceased
- 2017-09-06 EP EP24171603.4A patent/EP4385571A3/en active Pending
- 2017-09-06 KR KR1020237039437A patent/KR20230162996A/en not_active Ceased
- 2017-09-06 KR KR1020197009467A patent/KR102615565B1/en active Active
- 2017-09-06 AU AU2017324444A patent/AU2017324444A1/en not_active Abandoned
- 2017-09-06 MX MX2019002612A patent/MX2019002612A/en unknown
- 2017-09-06 CN CN202311201078.5A patent/CN117180280A/en active Pending
- 2017-09-06 EP EP17849478.7A patent/EP3509594B1/en active Active
- 2017-09-06 CN CN201780068871.9A patent/CN109922803B/en active Active
- 2017-09-06 BR BR112019004513A patent/BR112019004513A2/en not_active Application Discontinuation
- 2017-09-06 US US16/331,082 patent/US11793797B2/en active Active
- 2017-09-06 MA MA046203A patent/MA46203A/en unknown
- 2017-09-06 ES ES17849478T patent/ES3015717T3/en active Active
2019
- 2019-03-06 IL IL265232A patent/IL265232A/en unknown
2021
- 2021-02-03 US US17/166,689 patent/US20210177820A1/en not_active Abandoned
2024
- 2024-08-27 US US18/816,195 patent/US20240415824A1/en active Pending

Also Published As

Publication number	Publication date
CN117180280A (en)	2023-12-08
CN109922803A (en)	2019-06-21
US20210177820A1 (en)	2021-06-17
JP7097874B2 (en)	2022-07-08
EP3509594A4 (en)	2020-05-06
WO2018048942A1 (en)	2018-03-15
EP3509594A1 (en)	2019-07-17
US11793797B2 (en)	2023-10-24
US20190192495A1 (en)	2019-06-27
EP4052707A1 (en)	2022-09-07
AU2017324444A1 (en)	2019-04-11
ES3015717T3 (en)	2025-05-07
MA46203A (en)	2019-07-17
EP4385571A3 (en)	2024-08-28
JP2019526589A (en)	2019-09-19
BR112019004513A2 (en)	2019-06-18
CN109922803B (en)	2023-09-22
EP3509594B1 (en)	2025-02-26
IL265232A (en)	2019-05-30
MX2019002612A (en)	2019-08-21
KR102615565B1 (en)	2023-12-18
KR20230162996A (en)	2023-11-29
EP4385571A2 (en)	2024-06-19
KR20190065265A (en)	2019-06-11
CA3036062A1 (en)	2018-03-15
US20240415824A1 (en)	2024-12-19

Publication	Publication Date	Title
EP3509594C0 (en)	2025-02-26	LYSYL OXIDASE HOMOLOGUE 2 INHIBITOR FOR USE IN THE TREATMENT OF MYELOFIBROSIS
EP3393475C0 (en)	2025-02-05	CIFORADENT ALONE OR IN COMBINATION WITH ATÉZOLIZUMAB FOR USE IN THE TREATMENT OF CANCER
MA47719A (en)	2020-01-15	ESKETAMINE FOR THE TREATMENT OF DEPRESSION
MA52575A (en)	2021-03-17	DRESSING FOR THE TREATMENT OF DAMAGED SKIN
EP3600281A4 (en)	2020-03-18	ASSOCIATION TREATMENT FOR THE TREATMENT OR PREVENTION OF TUMORS
EP3642667C0 (en)	2023-06-07	ORTHOKERATOLOGY CONTACT LENS FOR THE TREATMENT OF MYOPIA
EP3359074A4 (en)	2019-09-18	ELECTROPORATION FOR THE TREATMENT OF OBESITY OR DIABETES
EP3504187A4 (en)	2020-05-06	USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE
EP3784260A4 (en)	2022-03-09	COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS
EP3298140A4 (en)	2019-07-24	COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CALCIFICATION STATES, AND METHODS USING THE SAME
MA53873A (en)	2022-01-19	COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA
EP3672650A4 (en)	2021-05-26	HYDROGEL FOR TISSUE ENGINEERING AND BIO-PRINTING
EP3440493A4 (en)	2019-05-22	SAMPLE TREATMENT FOR MICROSCOPY
EP3503890A4 (en)	2020-05-06	USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA
EP3405191A4 (en)	2019-09-04	METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERHIDROSIS
EP3512517A4 (en)	2020-05-06	USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION
EP3790563A4 (en)	2022-03-23	COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS
EP3458079A4 (en)	2020-03-04	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACNE
EP3434291A4 (en)	2019-10-23	COMPOSITION FOR THE TREATMENT OF AN INTERVERTEBRAL DISC
EP3541379A4 (en)	2020-05-27	COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
EP3426254A4 (en)	2019-11-27	USE OF BRAF INHIBITORS FOR THE TREATMENT OF SKIN REACTIONS
EP3773221A4 (en)	2021-09-15	TREATMENT FOR HYDROCEPHALIA
EP3493823C0 (en)	2024-12-25	POSTBIOTICS-BASED COMPOSITION FOR THE TREATMENT OF EYE INFECTIONS
MA45552A (en)	2019-05-08	COMPOSITIONS FOR THE TREATMENT OF AMYLOSIS
EP3344650A4 (en)	2019-04-17	AAV-EPO FOR THE TREATMENT OF PETS

Legal Events

Date	Code	Title	Description
2018-03-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-06-14	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-06-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-07-17	17P	Request for examination filed	Effective date: 20190312
2019-07-17	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-07-17	AX	Request for extension of the european patent	Extension state: BA ME
2019-08-07	RIN1	Information on inventor provided before grant (corrected)	Inventor name: HUTCHINSON, JOHN HOWARD Inventor name: BAIN, GRETCHEN Inventor name: EVANS, JILLIAN FRANCES Inventor name: MACKENNA, DEIDRE A.
2020-05-06	A4	Supplementary search report drawn up and despatched	Effective date: 20200407
2020-05-06	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/00 20060101ALI20200401BHEP Ipc: A61P 19/00 20060101ALI20200401BHEP Ipc: C07D 401/12 20060101ALI20200401BHEP Ipc: A61K 31/4439 20060101AFI20200401BHEP
2020-06-26	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40009578 Country of ref document: HK
2021-05-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-06-09	17Q	First examination report despatched	Effective date: 20210510
2024-07-29	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2024-07-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2024-08-14	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 1/16 20060101ALI20240711BHEP Ipc: A61P 13/12 20060101ALI20240711BHEP Ipc: A61K 31/519 20060101ALI20240711BHEP Ipc: C07D 401/12 20060101ALI20240711BHEP Ipc: A61P 29/00 20060101ALI20240711BHEP Ipc: A61P 37/02 20060101ALI20240711BHEP Ipc: A61P 27/02 20060101ALI20240711BHEP Ipc: A61P 19/00 20060101ALI20240711BHEP Ipc: A61P 35/00 20060101ALI20240711BHEP Ipc: A61K 31/4439 20060101AFI20240711BHEP
2024-08-28	INTG	Intention to grant announced	Effective date: 20240730
2025-01-16	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2025-01-24	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2025-01-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2025-02-26	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2025-02-26	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2025-02-28	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2025-03-20	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602017088046 Country of ref document: DE
2025-03-26	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2025-04-30	U01	Request for unitary effect filed	Effective date: 20250325
2025-04-30	U07	Unitary effect registered	Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20250331
2025-07-07	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250526
2025-07-09	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250226
2025-07-14	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250526 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250626
2025-07-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250226
2025-07-21	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250527
2025-10-06	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250226
2025-10-15	VS25	Lapsed in a validation state [announced via postgrant information from nat. office to epo]	Ref country code: MD Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250226
2025-10-22	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250226
2025-10-27	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250226